The present study found that upregulation of T-lymphokine-activated killer cell-originated protein kinase (TOPK), a serine/threonine protein kinase, is a new mechanism of resistance to gefitinib downstream of EGFR in NSCLC. The gene discussed is PBK; the disease is non-small cell lung carcinoma.